Calcium antagonists: on the way to expanding the indications

Full Text


The paper discusses indications for the use of long-acting dihydropyridine calcium blockers, such as felodipine, as well as perspectives for using this class of drugs.

About the authors

V V Fomin

I. M. Sechenov Moscow Medical Academy

Email: fomin
Кафедра терапии и профболезнейд-р мед. наук, доц; ММА им. И. М. Сеченова; I. M. Sechenov Moscow Medical Academy


  1. Российское медицинское общество по артериальной гипертонии - Всероссийское научное общество кардиологов. Диагностика и лечение артериальной гипертензии. Российские рекомендации (третий пересмотр). М.; 2008.
  2. Dahlof B., Sever P., Poulter N. R. ASCOT investigators. Prevention of cardiovascular events with antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendoflumethiazide as required in the Anglo- Scandinavian Cardiac Outcomes Trial: Blood Pressure Lowering Arm (ASCOT-BPLA): a multicenter randomized controlled trial. Lancet 2005; 366: 895-906.
  3. Ostergren J., Poulter N. R., Sever P. S. ASCOT investigators. The Anglo-Scandinavian Cardiac Outcomes Trial: blood pressure-lowering limb: effects in patients with type II diabetes. J. Hypertens. 2008; 26 (11): 2103-2111.
  4. Jameson K., Weber M. A., Bakris G. L ACCOMPLIISH trial investigators. Benazepril plus amloldipine or hydrochlorothiazide for hypertension in high-risk patients. N. Engl. J. Med. 2008; 359: 2417-2428.
  5. Staessen J. A., Fagard R., Thijs L. et al. Randomized double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997; 350: 757-764.
  6. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Effects of immediate versus delayed antihypertensive therapy on outcome in the Systolic Hypertension in Europe Trial. J. Hypertens. 2004; 22: 847-857.
  7. Forette F., Seux M. L., Staessen J. A. et al. Prevention of dementia in randomized double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) Trial. Lancet 1998; 352: 1347-1351.
  8. Voyaki S. M., Staessen J. A., Thijs L. et al. Follow-up of renal function in treated and untreated older patients with isolated systolic hypertension. Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. J. Hypertens. 2001; 19: 511-519.
  9. Liu L., Wang J. G., Gong L. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Systolic Hypertension in China (Syst-China) Collaborative Group. J. Hypertens. 1998; 16 (12, pt 1): 1823- 1829.
  10. Wang J. G., Staessen J. A., Fagard R. Risks of smoking in treated and untreated older Chinese patients with isolated systolic hypertension. J. Hypertens. 2001; 19: 187-192.
  11. Brown M. J., Palmer C. R., Castaigne A. et al. Morbidity and mortality in patients randomized to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356 (9227): 366-372.
  12. Mancia G., Brown M., Castaigne A. et al. INSIGHT. Outcomes with nifedipine GITS or Co-amilozide in hypertensive diabetics and nondiabetics in Intervention as a Goal in Hypertension (INSIGHT). Hypertension 2003; 41 (3): 431-436.
  13. Mancia G., Ruilope L., Palmer C. et al. Effects of nifedipine GITS and diuretics in isolated systolic hypertension - a subanalysis of the INSIGHT study. Blood Press. 2004; 13 (5): 310-315.
  14. Hansson L., Zanchetti A., Carruthers S. G. et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. HOT Study Group. Lancet 1998; 351 (9118): 1755-1762.
  15. Kjeldsen S. E., Kolloch R. E., Leonetti G. et al. Influence of gender and age on preventing cardiovascular disease by antihypertensive treatment and acetylsalicylic acid. The HOT study. Hypertension Optimal Treatment. J. Hypertens. 2000; 18 (5): 629-642.
  16. Liu L., Zhang Y., Liu G. FEVER Study Group. The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients. J. Hypertens. 2005; 23 (12): 2157-2172.
  17. Brun J., Fróberg L., Kronmann P. et al. Optimal felodipine dose when combined with metoprolol in arterial hypertension: a Swedish multicenter study within primary health care. Swedish General Practitioner Felodipine Study Group. J. Cardiovasc.Pharmacol. 1990; 15 (suppl. 4): S60-S64.
  18. Агеев Ф. Т., Деев А. Д. Применение фелодипина в амбулаторной практике: оценка клинической эффективности и приверженности к лечению у больных артериальной гипертензией. Кардиология 2009; 49 (1): 30-33.
  19. Podjarny E., Korzets Z., Bernheim J. Efficacy of low felodipine dose monotherapy in mild-to-moderate hypertension: a comparison between office an ambulatory blood pressure monitoring. J. Hum. Hypertens. 1996; 10 (suppl. 3): S153-S156.
  20. Ganz M. B., Saska B. A. Safety and efficacy of therapeutically equivalent doses of sustained-release formulations of isradipine and felodipine. Congest. Heart Fail. 2003; suppl. 2: 1-4.
  21. Lefebvre J., Poirier L., Archambault F. et al. Comparative effects of felodipine ER, amlodipine and nifedipine GITS on 24 h blood pressure control an trough to peak ratios in mild to moderate ambulatory hypertension: a forced titration study. Can. J. Cardiol. 1998; 14 (5): 628-682.
  22. Nussinovitch N., Carroll J., Shamiss A. et al. Felodipine in the treatment of severe refractory hypertension. J. Hum. Hypertens. 1996; 10 (suppl. 3): S165-S167.
  23. Parra D., Beckey N. P., Korman L. Retrospective evaluation of the conversion of amlodipine to alternative calcium channel blockers. Pharmacotherapy 2000; 20 (9): 1072-1078.
  24. Trachtman H., Frank R., Mahan J. D. et al. Clinical trial of extended-release felodipine in pediatric-essential hypertension. Pediatr. Nephrol. 2003; 18 (6): 548-553.
  25. Dougall H. T., McLay J. A comparative review of the adverse effects of calcium antagonists. Drug Saf. 1996; 15 (2): 91-106.
  26. Schaefer R. M., Aldons P. M., Burgess E. D. et al. Improved tolerability of felodipine compared with amlodipine in elderly hypertensives: a randomized, double-blind study in 535 patients, focusing on vasodilatory adverse events. The International Study Group. Int. J. Clin. Pract. 1998; 52 (6): 381-386.
  27. Bicchi M., Vedovini G., Cappelli R. et al. Effect of felodipine on arterial blood flow and venous function at rest in patients with mild essential hypertension. Angiology 1998; 49 (5): 373-380.
  28. Zanchetti A., Bold G., Hennig M. et al. Calcium antagonist lacidipin slows down progression of asymptomatic carotid atherosclerosis. Principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation 2002; 106: 2422-2427.
  29. Nissen S. E., Tuzcu E. M., Libby P. et al. CAMELOT investigators. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. J. A. M. A. 2004; 292 (18): 2217-2225.
  30. Song H., Bao W., Wang H. et al. Effects of extended-release felodipine on endothelial vasoactive substances in patients with essential hypertension. Clin. Chem. Lab. Med. 2008; 46 (3): 393-395.
  31. Рунихина Н. К., Ткачева О. Н. Эффективность пролонгированного антагониста кальция фелодипина у курящих женщин с эссенциальной артериальной гипертонией. Кардиология 2008; 48 (9): 50-52.
  32. Xing S. S., Tan H. W., Bi X. P. et al. Felodipine reduces cardiac expression of IL-18 and perivascular fibrosis in fructose-fed rats. Mol. Med. 2008; 14 (7-8): 395-402.
  33. Bi X. P., Tan H. W., Xing S. S. et al. Felodipine downregulates srum interleukin-18 levels in rats with fructose-induced metabolic syndrome. J. Endocrinol. Invest. 2009; 32 (4): 303-307.
  34. Tan H. W., Xing S. S., Bi X. P. et al. Felodipine attenuates vascular inflammation in a fructose-induced rat model of metabolic syndrome via the inhibition of NF-kappaB activation. Acta Pharmacol. Sin. 2008; 29 (9): 1051-1059.
  35. Yao R., Cheng X., Liao Y. H. et al. Molecular mechanisms of felodipine suppressing atherosclerosis in high-cholesterol-diet apolipoprotein E-knockout mice. J. Cardiovasc. Pharmacol. 2008; 51 (2): 188-195.
  36. Ruilope L. M., Salvetti A., Jamerson K. et al. Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. J. Am. Soc. Nephrol. 2001; 12 (2): 218-225.
  37. Schmitz A. Acute renal effects of oral felodipine in normal man. Eur. J. Clin. Pharmacol. 1987; 32 (1): 17-22.
  38. Lernfelt B., Landahl S., Johansson P. et al. Haemodynamic and renal effects of felodipine in young and elderly subjects. Eur. J. Clin. Pharmacol. 1998; 54 (8): 595-601.
  39. Hasselgren B., Edgar B., Johnsson G., Rónn O. The acute haemodynamic and renal effects of oral felodipine and ramipril in healthy subjects. Eur. J. Clin. Pharmacol. 1993; 45 (4): 327-332.
  40. Huysmans F. T., van Hamersvelt H. W., Sluiter H. E. et al. Acute renal effects of felodipine in hypertensive patients with kidney disease. Kidney Int. Suppl. 1992; 36: S106-S109.
  41. Herlitz H., Harris K., Risler T. et al. The effects of an ACE inhibitor and a calcium antagonist on the progression of renal disease: the Nephros Study. Nephrol. Dial. Transplant. 2001; 16 (11): 2158-2165.
  42. Tanabe K. Calcineurin inhibitors in renal trasplantation: what is the best option? Drugs 2003; 63: 1535-1548.
  43. Cattran D. C., Alexopoulos E., Heering P. et al. Cyclosporin in idiopathic glomerular disease associated with the nephritic syndrome: workshop recommendations. Kidney Int. 2007; 72 (12): 1429-1447.
  44. Sórensen S. S., Skovbon H., Eiskjaer H. et al. Effect of felodipine on renal haemodynamics and tubular sodium handling in cyclosporin-treated renal transplant recipients. Nephrol. Dial. Transplant. 1992; 7 (1): 69-78.
  45. Pedersen E. B., Madsen J. K., Sórensen S. S., Zachariae H. Improvement in renal function by felodipine during cyclosporine treatment in acute and short-term studies. Kidney Int. Suppl. 1996; 55: S94-S96.
  46. Madsen J. K., Sórensen S. S., Hansen H. E., Pedersen E. B. The effect of felodipine on renal function and blood pressure in cyclosporin-treated renal transplant recipients during the first three months after transplantation. Nephrol. Dial. Transplant. 1998; 13 (9): 2327-2334.
  47. Bratel T., Hedenstierna G., Nyquist O., Ripe E. The use of a vasodilator, felodipine, as an adjuvant to long-term oxygen treatment in COLD patients. Eur. Respir. J. 1990; 3 (1): 46-54.
  48. Sajkov D., McEvoy R. D., Cowie R. J. et al. Felodipine improves pulmonary hemodynamics in chronic obstructive pulmonary disease. Chest 1993; 103 (5): 1354-1361.
  49. Sajkov D., Wang T., Frith P. A. et al. A comparison of two long-acting vasoselective calcium antagonists in pulmonary hypertension secondary to COPD. Chest 1997; 111 (6): 1622- 1630.
  50. Чазова И. Е., Литвин А. Ю. Артериальная гипертония и синдром обструктивного апноэ во время сна. В кн.: Чазов Е. И., Чазова И. Е. Руководство по артериальной гипертонии. М.: Media Medica; 2005. 182-200.



Abstract: 145

Article Metrics

Metrics Loading ...


  • There are currently no refbacks.

Copyright (c) 2010 Fomin V.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Novoslobodskaya str 31c4., Moscow, 127005, Russian Federation

Managing Editor:


© 2018-2021 "Consilium Medicum" Publishing house

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies